SRA
AKRO

Summit Rock Advisors’s Akero Therapeutics AKRO Stock Holding History

Summit Rock Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,891
Closed -$384K – 8
2020
Q4 		$384K Buy
+14,891
New +$414K 0.13% 9

Other funds holding AKRO

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Rock Advisors's AKRO Position: Q1 2021 in Review

Summit Rock Advisors sold out of Akero Therapeutics (AKRO) in Q1 2021, closing a stake of 14,891 shares — an estimated $384K sold.

Summit Rock Advisors first reported a position in AKRO in Q4 2020 and held it in 1 quarter. The position peaked at $384K in Q4 2020. 109 funds tracked by Wall St. Rank hold AKRO as of Q1 2021.

  • Summit Rock Advisors reported no remaining Akero Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Summit Rock Advisors sold 14,891 Akero Therapeutics shares in Q1 2021, an estimated $384K.
  • Summit Rock Advisors first reported a position in Akero Therapeutics in Q4 2020 and held it in 1 quarter.
  • Summit Rock Advisors's Akero Therapeutics position peaked at $384K in Q4 2020.
  • 109 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2021.

Based on Summit Rock Advisors's 13F filing for Q1 2021, filed 13 May 2021.